NFTG(US:NFTG)2025-08-13 20:00Revenue Generation - In Q2 2025, the company generated revenues of $170,971, primarily from RNK Health, with $170,398 from non-clinical services, compared to no revenue in Q2 2024[120]. - For the first half of 2025, revenues totaled $194,703, with $192,950 from RNK Health, an increase from $19 in the same period of 2024[121]. Operating Expenses - Operating expenses in Q2 2025 were $1,153,665, a 35.0% increase from $854,503 in Q2 2024; for the first half of 2025, expenses were $2,569,092, up 35.3% from $1,898,361[122]. - General and administrative expenses in Q2 2025 totaled $910,645, up 50.5% from $605,162 in Q2 2024; for the first half, they reached $2,105,083, an increase of 43.5% from $1,466,691[127]. - Compensation and related benefits increased by 20.3% in Q2 2025 to $184,753, and by 49.6% in the first half to $773,738, primarily due to executive bonuses[128][129]. - Professional fees decreased by 55.9% in Q2 2025 to $125,956, and by 36.0% in the first half to $358,847, mainly due to reduced advisory and legal fees[130]. - For the three months ended June 30, 2025, other general and administrative expenses increased by $434,025, or 261.6%, totaling $599,936, primarily due to increased advertising and marketing fees[132]. Losses and Financial Position - The loss from operations for the three months ended June 30, 2025, was $982,694, an increase of $128,191, or 15.0%, compared to the same period in 2024[134]. - Net loss attributable to common shareholders for the three months ended June 30, 2025, was $749,388, or $0.11 per common share, a decrease of $59,850, or 7.4%, from the previous year[137]. - As of June 30, 2025, the company had a cash balance of $1,718,964 and short-term investments of $12,326,666, resulting in total working capital of $13,992,440[139]. - For the six months ended June 30, 2025, net cash used in operations was $2,014,345, primarily due to a net loss of $2,056,634[142]. - The company reported other income of $158,122 for the three months ended June 30, 2025, compared to $45,265 in the same period of 2024, reflecting gains on short-term investments[136]. - For the six months ended June 30, 2025, net cash used in investing activities was $10,664,790, primarily due to the purchase of short-term investments[144]. - The company expects to continue generating operating losses in the foreseeable future due to corporate overhead and research and development costs[141]. Research and Development - Research and development fees for Q2 2025 were $243,020, a slight decrease of 2.5% from $249,341 in Q2 2024, while for the first half, they increased by 7.5% to $464,009[124][126]. - The company plans to pursue research and development of new products, which will require additional capital from third-party sources[148]. New Initiatives - Gaxos Labs launched in September 2024, offering a generative AI service for game developers, enabling the creation of unique in-game features and NFTs[109]. - Gaxos Health, initiated in Q3 2024, aims to provide AI-driven personalized health optimization solutions, integrating biometric data with wellness strategies[112][113]. - RNK Health, a subsidiary formed in September 2024, holds a 70% interest in partnership with Nekwellness to market health-related products and services[114].